Curiox Biosystems and Beckman Coulter Life Sciences Announce a Partnership Combining C-FREE™ Technology with DURA Innovations for Hands-Free Washed Sample Preparation for Flow Cytometry

Rhea-AI Summary

Curiox Biosystems and Beckman Coulter Life Sciences have announced a partnership to provide researchers with a one-stop solution for hands-free washed sample preparation for flow cytometry, combining C-FREE™ technology with DURA Innovations. The collaboration aims to address challenges in standardization, automation, and reproducibility, paving the way for advancements in research and healthcare.

Positive

• Partnership expected to accelerate research and development of next-generation therapies, vaccines, and biomanufacturing processes.

Negative

• None.

WOBURN, Mass., May 3, 2024 /PRNewswire/ -- Curiox Biosystems Co. Ltd (Curiox), a leader in the innovation of life science research technologies, and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, announce a strategic partnership to provide researchers with a one-stop solution for hands-free washed sample preparation for flow cytometry.

The agreement combines the Laminar flow-based gentle liquid exchange technology known as C-FREE™ technology from Curiox with the comprehensive suite of DURAClone dry pre-formulated antibody panels and customized DURA Innovations dry reagent antibody cocktails from Beckman Coulter Life Sciences. This workflow solution overcomes longstanding challenges faced by researchers worldwide, including the need for highly standardized, reproducible, and automated sample preparation for flow cytometry laboratories.

"Our alliance with Beckman Coulter Life Sciences is not just about combining technologies; it's about combining our strengths to empower the scientific community," said Namyong Kim. PhD, CEO of Curiox Biosystems. "By addressing the challenges of standardization, automation, and reproducibility head-on, we are paving the way for significant advancements in research and healthcare."

"Speed and accuracy are of the utmost importance in delivering results to researchers to enable them to make critical decisions on their journey to pioneering new discoveries," said Pietro Lopriore, Vice President and General Manager of Flow Cytometry at Beckman Coulter Life Sciences. "This partnership presents an exciting step forward in redefining the standards of quality and efficiency in flow cytometry research. By being a trusted partner to the scientific community, we're able to combine complementary technologies to unite in a common goal of advancing research to positively impact lives."

This partnership is expected to accelerate the research and development of next-generation therapies, vaccines, and biomanufacturing processes.

About Curiox Biosystems Co. Ltd
Curiox Biosystems Co. Ltd is a rapidly growing global biotechnology company specializing in advanced sample preparation solutions that enhance next-generation therapies. The company leverages expertise in surface chemistry and instrumentation to address life-science research challenges, particularly in miniaturization and automation. Curiox's innovative technologies boost productivity through sample preparation automation, speeding up therapeutic development. Committed to advancing its proprietary C-FREE™ technology, Curiox enables significant scientific breakthroughs, reinforcing its role as a key player in transforming life sciences research and diagnostics worldwide. Visit us at https://www.curiox.com/

About Beckman Coulter Life Sciences

With a relentless mission to empower those seeking answers to life's important scientific questions, Beckman Coulter Life Sciences is a preferred laboratory partner providing automation and innovation solutions for Centrifugation, Flow Cytometry, Genomics, Particle Analysis, and Liquid Handling workflows. With a legacy dating back to 1935, our technologies reduce manual laboratory processes and can provide greater speed, accuracy, and advanced analytics to accelerate answers with a guiding focus to improve patient care and enable pioneering discoveries. Beckman Coulter Life Sciences, part of the Danaher Corporation (NYSE: DHR) family of global science and technology companies, is headquartered in Indianapolis, Indiana with 11 operational hubs around the world and employs approximately 2,800 associates with more than 400,000 systems installed globally. Get to know us by clicking here and by following us on LinkedIn.

Contact Information:
For Curiox Biosystems Co. Ltd:
Attn: Mahrukh M Banday, EVP/GM
mahib@curiox.com
USA: 400 W Cummings Park #6650, Woburn, MA 01801
Corporate office
#212 Samsung Harrington IT Tower, 9 Gil 41 Digital-Ro, Geumchun-Gu, Seoul 08511, Korea

For Beckman Coulter Life Sciences:
Matt McCutcheon, Global External Communications Manager
(317) 719-0557 or mmccutcheon@beckman.com

For Research Use Only (RUO). Not for use in diagnostic procedures.

Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. All other trademarks are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/curiox-biosystems-and-beckman-coulter-life-sciences-announce-a-partnership-combining-c-free-technology-with-dura--innovations-for-hands-free-washed-sample-preparation-for-flow-cytometry-302135355.html

SOURCE Curiox Biosystems

FAQ

What is the partnership between Curiox Biosystems and Beckman Coulter Life Sciences about?

The partnership aims to provide researchers with a one-stop solution for hands-free washed sample preparation for flow cytometry.

What technologies are being combined in the partnership?

The partnership combines C-FREE™ technology from Curiox with DURA Innovations from Beckman Coulter Life Sciences.

What challenges does the collaboration aim to overcome?

The collaboration aims to address challenges in standardization, automation, and reproducibility in flow cytometry laboratories.

What is the goal of the partnership for the scientific community?

The goal is to advance research and healthcare by empowering the scientific community with improved standards of quality and efficiency.

How will the partnership impact research outcomes?

The partnership is expected to accelerate the research and development of next-generation therapies, vaccines, and biomanufacturing processes.